Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 3/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.50 |
| ▸ | ESR1 | P03372 | 3/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | GUSB | P08236 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17196524 | 0.85 | CYP1A2 (0.48) | ALKDYRK1ADYRK1BRPS6KA3CYP1A2 | |
| SCHEMBL12286155 | 0.84 | CYP1A2 (0.52) | ALKDYRK1ADYRK1BESR1ESR2 | |
| SCHEMBL5953232 | 0.76 | ITK (0.52) | DYRK1BRPS6KA3TNKSGUSBPARP1 | |
| SCHEMBL22801606 | 0.76 | MAP2K4 (0.56) | ALKDYRK1ADYRK1BDYRK3GSK3B | |
| SCHEMBL22801717 | 0.73 | MAP2K4 (0.59) | ALKDYRK1ADYRK1BRPS6KA3DYRK3 | |
| SCHEMBL16178927 | 0.71 | CYP1A2 (0.56) | CYP1A2CYP2C19NOS1TNKSGUSB | |
| SCHEMBL17692468 | 0.71 | CYP1A2 (0.60) | CYP1A2CYP2C19NOS1PARP1TNKS2 | |
| Hydrochloric Acid SCHEMBL30262984 | 0.70 | CYP1A2 (0.54) | CYP1A2CYP2C19NOS1TNKSGUSB | |
| SCHEMBL12075154 | 0.69 | CYP1A2 (0.48) | CYP1A2CYP2C19NOS1MEN1KMT2A | |
| SCHEMBL18627081 | 0.69 | CYP1A2 (0.48) | CYP1A2CYP2C19NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7304073-B2 | Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors | WYETH (US) | 2007-12-04 | — | — | US | disclosed |
| CN-101054364-A | Substituted 4-(indazol-3-yl)phenols as estrogen receptor (ER) ligands and their use in the treatmentof inflammarory diseases | WYETH CORP (US) | 2007-10-17 | — | — | CN | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| CN-1321984-C | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| US-20060111421-A1 | Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors | WYETH (US) | 2006-05-25 | — | — | US | disclosed |
| CN-1692102-A | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2005-11-02 | — | — | CN | disclosed |
| EP-1542976-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Wyeth (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050119276-A1 | Methods of treating inflammatory bowel disease using NF-kB inhibitors | WYETH (US) | 2005-06-02 | — | — | US | disclosed |
| US-20050119324-A1 | Methods of treating atherosclerosis using NF-kB inhibitors | WYETH (US) | 2005-06-02 | — | — | US | disclosed |
| US-20050113405-A1 | Methods of treating rheumatoid arthritis using NF-kB inhibitors | WYETH (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2005039582-A1 | METHODS OF TREATING ATHEROSCLEROSIS USING NF-kB INHIBITORS | WYETH (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004031159-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | ALK 2511/4885DYRK1A 1771/4885DYRK1B 1434/4885 |
| US-20050113405-A1 | Methods of treating rheumatoid arthritis using NF-kB inhibitors | NFKBIA, IKBKB, IKBKG | ALK 1271/4885DYRK1A 1778/4885DYRK1B 1146/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | ALK 3201/4885DYRK1A 1865/4885DYRK1B 1764/4885 |
| US-20050119324-A1 | Methods of treating atherosclerosis using NF-kB inhibitors | NFKBIA, IKBKB, IKBKG | ALK 1438/4885DYRK1A 2117/4885DYRK1B 1421/4885 |
| US-20060111421-A1 | Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors | IKBKB, NFKBIA, IKBKG | ALK 3486/4885DYRK1A 2567/4885DYRK1B 1700/4885 |
| US-20050119276-A1 | Methods of treating inflammatory bowel disease using NF-kB inhibitors | NFKBIA, IKBKB, IKBKG | ALK 1849/4885DYRK1A 1542/4885DYRK1B 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.